Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Klaudia Kuranda, … , Philippe Veron, Federico Mingozzi
Klaudia Kuranda, … , Philippe Veron, Federico Mingozzi
Published October 22, 2018
Citation Information: J Clin Invest. 2018;128(12):5267-5279. https://doi.org/10.1172/JCI122372.
View: Text | PDF
Research Article Immunology

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans

  • Text
  • PDF
Abstract

Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.

Authors

Klaudia Kuranda, Priscilla Jean-Alphonse, Christian Leborgne, Romain Hardet, Fanny Collaud, Solenne Marmier, Helena Costa Verdera, Giuseppe Ronzitti, Philippe Veron, Federico Mingozzi

×

Figure 3

Identification of capsid-specific IFN-γ+CD16brightCD56dim NK cells in AAV-seronegative individuals.

Options: View larger image (or click on image) Download as PowerPoint
Identification of capsid-specific IFN-γ+CD16brightCD56dim NK cells in AA...
(A) Flow cytometric plots showing IFN-γ and TNF-α staining of NK cells, 24 hours after stimulation of PBMCs with the AAV2 pool of peptides or in control cultures without antigen. (B) Fold change of IFN-γ concentration in the culture medium of PBMCs, measured by Luminex assay 24 hours after stimulation with the AAV2 pool of peptides. (C) Kinetics of IFN-γ and TNF-α secretion and CD107a levels in CD16brightCD56dim NK cells 6, 24, and 48 hours after stimulation with the AAV2 pool of peptides (n = 4). Box plots show the median ± SD. (D) Percentage of cytokine-positive CD16brightCD56dim NK cells 24 hours after restimulation with the indicated antigens. (E) Heatmap representing the percentage of IFN-γ+ or TNF-α+CD16brightCD56dim NK cells 24 hours after stimulation with the AAV2 pool of peptides. The percentage of healthy donors in each category is shown. (F) Percentage of IFN-γ+ or TNF-α+CD16brightCD56dim NK cells 24 hours after stimulation with the AAV2 pool of peptides measured in AAV2-seronegative or -seropositive donors. Box plots show the median ± SD. In B and D, the histograms show the mean, and the symbols represent individual sample values. Dashed lines indicate the cutoff for positivity. *P < 0.05 and ****P < 0.0001, by Wilcoxon signed-rank test (A), nonparametric Kruskal-Wallis 1-way ANOVA with Dunn’s multiple comparisons test (D), and nonparametric Mann-Whitney U test (F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts